Back

A clinical view on BET inhibition in targeting residual risk in cardiovascular disease and diabetes.

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: LDL-c: done deal, next epigenetics? (EBAC Accredited) Secondary Prevention ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Introduction - LDL-c: done deal, next epigenetics?
Professor U. Laufs (Leipzig, DE)
Presentation thumbnail
The real residual risk in patients with cardiovascular disease and diabetes: the promise of epigenetics.
Professor E. Stroes (Amsterdam, NL)
Presentation thumbnail
Understanding epigenetics - The potential rationale for BET inhibition in management of cardiovascular disease.
Doctor J. Plutzky (Boston, US)
Presentation thumbnail
Discussion and summary - LDL-c: done deal, next epigenetics? .
Professor U. Laufs (Leipzig, DE)

Access the full session

Session thumbnail
LDL-c: done deal, next epigenetics? (EBAC Accredited)

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
Making personalised prevention everyone's business
thumbnail
Congress Presentation
Should we intervene early in patients with asymptomatic aortic stenosis?
thumbnail
Congress Presentation
Cardiovascular prevention in older adults

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources